We and others have demonstrated already that TRAIL (TNF-related apoptosis-inducing ligand) is a very promising candidate for molecular targeted anticancer therapy, especially when combined with ionizing radiation or other DNA-damaging agents. Agonist monoclonal antibodies that activate and are specific for the death signaling TRAIL receptors are an alternative method to stimulate the programmed cell death pathway. Phase 1 clinical trials have subsequently been conducted and shown a very good tolerability of these antibodies. In order to assess the efficacy of TRAIL receptor stimulation to induce cell death by this alternate method, we studied the combination of the agonistic-TRAIL receptor antibodies HGS-ETR1 and HGS-ETR2 with radiation in vitro and in vivo. Induction of apoptosis after combined treatment with TRAIL receptor antibodies HGS-ETR1 and/or HGS-ETR2 (0.01, 0.1, 1.0 mg/ml) and irradiation with 2, 5 or 10 Gy was determined by fluorescence microscopy and Western blot analysis of caspase-8 and PARP. The colorectal tumour cell lines Colo 205, HCT 116 and HCT-15 were used for in vitro experiments. Growth delay experiments were performed with combined treatment with fractionated irradiation (days 1-5 and 3 Gy single dose/day) and the receptor antibodies (intraperitonially, three different concentrations, application on days 1, 4 and 8) on Colo 205 xenograft-bearing NMRI (nu/nu) nude mice. HGS-ETR1 and HGS-ETR2 induced apoptotic cell death in a dose-dependent fashion and significantly increased cell death in combination with irradiation in vitro when compared to either irradiation or antibody treatment alone. The efficacy of the combined treatment seems to be at least partially Bax-dependent. Similar to the results from cell culture experiments, in vivo experiments demonstrated a dose-dependent delay in tumour growth after combined treatment. In vivo, in the Colo205 xenograft model, HGS-ETR2 revealed a higher activity than HGS-ETR1. This is the first study to demonstrate significant efficacy of combined treatment with the monoclonal agonistic TRAIL receptor antibodies HGS-ETR1 and HGS-ETR2 and ionising radiation in in vitro and in vivo models. We postulate that HGS-ETR1 and HGS-ETR2 will be very promising new agents in the field of molecular targeted multi-modality anticancer therapy.
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Introduction
Colorectal tumours are one of the most frequently diagnosed malignancies in the Western industrial countries. Surgical treatment for locally advanced disease alone remains unsatisfactory. The combination of surgery and neoadjuvant or adjuvant chemoradiotherapy increases the cure rate. However, the current conventional therapies fail to cure about 40-70% of locally advanced cancers, mainly owing to treatment resistance or poor tolerance of treatment because of severe side effects. Therefore, overcoming resistance and developing therapies with selective, cell type-specific induction of cell death while eliminating side effects are still the primary goals of cancer treatment.
TRAIL (TNF-related apoptosis-inducing ligand) induces apoptosis in a wide range of haematopoietic and solid tumour cells, while sparing most normal cells (Ashkenazi et al., 1999; Walczak et al., 1999; Belka et al., 2001; Almasan and Ashkenazi, 2003; LeBlanc and Ashkenazi, 2003; Marini et al., 2005) . After activation of its receptors TRAIL-R1 (DR4) and TRAIL-R2 (DR5), the fas-associated death domain adapter molecule is recruited to the receptor, leading to an autoproteolytic cleavage and activation of initiator caspase-8 (Muzio et al., 1996; Chaudhary et al., 1997; Schneider et al., 1997) . Active caspase-8 in turn triggers the proteolytic activation of downstream caspases including caspase-3. Downstream caspases ultimately degrade a broad range of cellular proteins, and apoptosis is finalized (for review see Stroh and Schulze-Osthoff, 1998; Fischer et al., 2003) .
In contrast to extrinsic or receptor-mediated apoptosis, radiation-or chemotherapy-induced DNA damage triggers apoptosis mainly via the intrinsic or mitochondrial death pathways (for review see Debatin et al., 2002; Norbury and Zhivotovsky, 2004) . A key step in mitochondrial apoptosis is the mitochondrial release of proapoptotic mediators including cytochrome c. This release is generally controlled by a complex interplay of proapoptotic members of the B-cell lymphoma (Bcl)-2 family. Bcl-2 itself is an antiapoptotic protein, which reduces TRAIL-mediated apoptosis depending on cell type and TRAIL dose (Rudner et al., 2005) . Activation of proapoptotic members of the Bcl-2 family namely Bax, Bak, Noxa and Puma may occur directly via conformational changes (Daniel et al., 2003) or transcriptional upregulation (Miyashita and Reed, 1995; Nakano and Vousden, 2001) . The presence of Bax or Bak seems to be essential for apoptosis in many cell types (Wei et al., 2001; Zong et al., 2001; Daniel et al., 2003; von Haefen et al., 2004) .
Inactivated Bax is located in the cytosol and integrates during apoptosis to the outer mitochondrial membrane, where it oligomerizes. Bak is an oligomeric integral mitochondrial protein, which forms larger aggregates during cell death (Nechushtan et al., 2001) . In some cell systems, Bax and Bak seem to have redundant functions, as both might contribute to the permeabilization of the mitochondrial membrane, allowing the efflux of proapoptotic molecules like cytochrome c. Cytochrome c released from the mitochondria triggers the activation of caspase-9 by association with apoptotic protease-activating factor -1 in an ATP-dependent manner (Li et al., 1997; Cecconi, 1999) . Caspase-9 subsequently activates the downstream effector caspase cascade including caspase-3 and, in analogy to receptor-mediated apoptosis, cell death is finalized.
Combination of receptor and mitochondrial triggered apoptosis might overcome drug resistance of cancer cells. Generally, receptor stimulation can be achieved directly by binding of a specific ligand or, alternatively, by receptor-specific antibodies. HGS-ETR1 and HGS-ETR2 are high-affinity, recombinant, fully human, IgG 1 l monoclonal antibodies agonistic and specific to cell death receptors TRAIL-R1 or TRAIL-R2, respectively (Salcedo et al., 2002; Alderson et al., 2003; Pukac et al., 2005) . Phase I clinical studies in patients with advanced, incurable solid malignancies as well as nonHodgkin's lymphomas have been initiated and some evidence of biological activity has been demonstrated (de Bono et al., 2004; Hotte et al., 2004; Attard et al., 2005; Sarantopoulos et al., 2005) . Thus far, these antibodies have been well tolerated, with nonspecific CTC grade 3 toxicity reported in only three of 42 patients (asymptomatic raise of serum amylase, hypertension, thrombocytopenia). No hepatotoxicity has been observed up to now.
Recently, we have demonstrated synergistic effects of the receptor ligand TRAIL with irradiation in different tumour cell lines without relevant toxicity to normal tissues (Belka et al., 2001; Marini et al., 2005) . However, we hypothesized that antibody-based death receptor stimulation combined with irradiation represents an alternative and possibly more specific therapy.
Our data are the first to demonstrate induction of apoptosis and growth delay for the combined treatment with the novel agonistic TRAIL receptor antibodies, HGS-ETR1 and HGS-ETR 2, with irradiation in a panel of colorectal tumour cell lines and in a xenograft mouse model.
Results
Combined treatment with TRAIL receptor antibodies and irradiation increases cell death Cell surface expression of the TRAIL receptors TRAIL-R1 and TRAIL-R2 was quantified in the untreated colorectal cell lines Colo 205, HCT-15 and HCT 116 wild type (wt) with HCT 116 knockout (k/o) by flow cytometry. TRAIL-R2 was highly expressed in all three cell lines. TRAIL-R1 was expressed at high levels only in one of the three cell lines, HCT-15 (Figure 1) .
To determine the optimal therapeutic antibody concentration, irradiation dose and duration in the setting of combined therapy, we treated all cell lines with HGS-ETR1, HGS-ETR2, HGS-ETR1 þ HGS-ETR2 and ionizing radiation, separately. Both antibodies induced apoptosis in a dose-and time-dependent fashion in all three tested cell lines (Figure 2a ). Simultaneous treatment with both antibodies enhanced cell death by 10-20% compared to treatment with either antibody alone. In Colo 205 cells, dose-and timedependent induction of apoptosis in up to 46% of cells within 48 h after irradiation with 2, 5 or 10 Gy occurred. In HCT-15 cells, apoptosis occurred only at a very low level of 10% within 48 h after treatment and only at the highest level of radiation, at 10 Gy. HCT 116 wt cells were nearly resistant to radiation at a level of apoptosis of less than 5% (Figure 2b ).
All three tumour cell lines were subjected to a combination of antibody-induced receptor stimulation and ionizing radiation in order to assess the increment in apoptotic cell death. Three different doses of either anti-TRAIL receptor antibody alone or in combination with irradiation (2, 5 or 10 Gy) were applied to all cell lines. Irradiation with 10 Gy induced the highest level of apoptosis. Figure 3 shows cell death after irradiation with 10 Gy and application of antibodies at a concentration of 0.1 (Colo 205, HCT-15) or 1 mg/ml (HCT 116 wt). The highest increase in apoptosis with combined treatment over either single treatment was reached in Colo 205 cells. When treated with HGS-ETR1 and irradiation, Colo 205 cells underwent apoptosis in up to 89% of the cells after 48 h. When treated in the same way with HGS-ETR2 and irradiation, apoptosis reached 90%. In HCT-15 cells, 43 and 55% of cells were apoptotic 48 h after combined treatment with irradiation at 10 Gy and either HGS-ETR1 or HGS-ETR2, respectively. Interestingly, in HCT 116 wt cells, whereas irradiation alone could not induce a significant level of cell death, irradiation combined with HGS-ETR1 increased apoptosis from 16% (antibody alone) to 30% and in combination with HGS-ETR2 apoptosis increased from 19 to 36% after 48 h. Combination of both antibodies with irradiation led to an insignificant increase in cell death when compared to either antibody in combination with radiation ( Figure 3 ).
Sequential application of HGS-ETR1 and HGS-ETR2 after irradiation increases apoptotic cell death
Recently, we demonstrated that irradiation sensitizes tumour cells to TRAIL-induced apoptosis (Belka et al., 2001; Marini et al., 2005) . To determine whether the same effect could be achieved with anti-TRAIL receptor antibodies, all three colorectal tumour cell lines were treated with HGS-ETR1 or HGS-ETR2 12 h after irradiation. Sequential application of HGS-ETR1 after irradiation increased the level of apoptosis by 13% in Colo 205 and HCT-15 cells compared to simultaneous treatment ( Figure 4 ). Sequential treatment with HGS-ETR2 after irradiation increased cell death by approximately 3% in Colo 205 and by 6% in HCT-15 cells. Combination of both antibodies did not lead to a significant increase in these two cell lines. Interestingly, whereas treatment with HGS-ETR1 alone following irradiation had no effect in HCT 116 cells, treatment with either HGS-ETR2 or both antibodies increased apoptotic cell death by 12 and 33% in these cells, respectively.
No increase in apoptosis was detected when treatment with the agonistic TRAIL receptor antibodies preceded irradiation (data not shown).
Cell death is mediated by cleavage of proapoptotic proteins
To prove that the mechanism of cell death was mediated through apoptosis, caspase-8 activation and the processing of the caspase-3 substrate Poly(ADP-ribose) polymerase (PARP) was analysed 12 h after treatment. In keeping with the above results, the most prominent increase in caspase-8 and PARP processing was found in Colo 205 and HCT-15 cells 12 h after irradiation followed by HGS ETR1 or HGS-ETR2.
The effect was less pronounced in HCT 116 wt cells ( Figure 5 ). These data correlate well with the kinetics of apoptosis induction as determined by fluorescence microscopy of Hoechst-stained cells (Figures 2 and 3 ).
Cell death by combined treatment with anti-TRAIL receptor antibodies and irradiation is Bax dependent
To gain insight into the molecular basis of the increased efficacy of a combined treatment with anti-TRAIL receptor antibodies and ionizing radiation, we examined the involvement of the proapoptotic Bcl-2 family member Bax, which acts via the mitochondrial apoptosis Combined therapy with agonistic TRAIL antibodies and radiotherapy P Marini et al pathway. Therefore, we examined the HCT 116-Bax À/À cell line, in which the Bax gene was knocked out by targeted gene disruption (Zhang et al., 2000) . Depending on cell line and apoptotic stimulus, the proapoptotic Bcl-2 homologues Bax and Bak might act in a redundant manner (Daniel et al., 2003; Nechushtan et al., 2001; Wei et al., 2001) . Therefore, we looked for Bax and Bak expression in both HCT 116 cell lines by protein analysis (Figure 6 ). As expected, HCT 116 Bax Combined therapy with agonistic TRAIL antibodies and radiotherapy P Marini et al compared to irradiation alone after addition of HGS-ETR1 and from 19 to 51% when HGS-ETR2 was applied following irradiation. When irradiation (10 Gy) and both antibodies were applied simultaneously, an increase in cell death from 27 to 70% was noted. This effect was less pronounced at lower (2 and 5 Gy) doses of irradiation (data not shown). No enhancement of cell death after combined treatment was observed in HCT 116-Bax À/À cells with maximal rates of apoptosis below 10%. This suggests that the efficacy of a combined treatment with agonistic anti-TRAIL receptor antibodies HGS-ETR1 or HGS-ETR2 with ionizing radiation is Bax dependent.
HGS-ETR1 and HGS-ETR2 have an increased antitumour effect in vivo when combined with irradiation Intraperitoneal application of HGS-ETR1 was performed three times in 8 days at concentrations of 0.1, 1.0 or 10 mg/kg. Analysis of tumour growth delay data for combined modality treatment with HGS-ETR1 and fractionated irradiation (5 Â 3 Gy over 5 days) demonstrated a significant increase in tumour growth reduction. Table 1 shows the results of these experiments. The most prominent effect was observed after treatment with 10 mg HGS-ETR1/kg body weight. The median doubling time of tumour size was 5.6 days for untreated animals, 5.3 days after fractionated irradiation, 27.6 days after treatment with HGS-ETR1 alone and up to 71 days after combined treatment. HGS-ETR2 antibody applied according to the same dosing schedule led to greatly increased tumour regression. At a dose of 10 mg/ kg body weight, tumour regression was apparent after the first of three applications. After treatment with the highest dose at 10 mg/kg body weight alone, six out of nine animals were cured, that is, no tumour was identifiable at the implantation site. Thus, overall growth delay was improved from 5.6 (untreated animals) to 115.4 days. Irradiation had no additional effect (116.0 days); six out of eight animals were cured. Intercurrent deaths of single animals as well as the large number of tumour cure after treatment with high doses of HGS-ETR2 were statistically corrected according to a Kaplan-Meier-based method modified by Stuschke et al. (1990) . Figure 7 illustrates the dose-dependent local tumour control for HGS-ETR1 and HGS-ETR2 in combination with irradiation over time.
Discussion
New molecular targeted anticancer agents such as receptor-specific antibodies promise to become specific and potent therapies. The stimulation of TRAIL receptors, which are members of the still growing death receptor family, is known to induce tumour cell-specific apoptosis in a broad range of tumours with nearly no toxicity affecting normal tissues in vitro and in vivo (Ashkenazi et al., 1999; Walczak et al., 1999; Marini et al., 2005) . Receptor stimulation . Figure 3 Time course of induction of apoptosis in three colorectal cell lines after combined treatment. Apoptosis was determined by microscopic evaluation of Hoechst-stained cell nuclei 24-48 h after simultaneous treatment of Colo 205 and HCT-15 cells with 0.1 mg/ ml HGS-ETR1 or HGS-ETR2 (or both antibodies together) and 10 Gy. HCT 116 wild-type cells were treated with 1.0 mg/ml HGS-ETR1 or HGS-ETR2 (or both antibodies together) and 10 Gy. Data represent means of three independent experiments; bars7s.d.
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by TRAIL is also effective in tumour cells under hypoxic conditions, which reduces the efficacy of radiotherapy and many types of chemotherapy (Harris, 2002; Weinmann et al., 2004a, b) . HGS-ETR1 binds to the TRAIL receptor 1 and HGS-ETR2 binds to the TRAIL receptor 2 (Salcedo et al., 2002; Tolcher et al., 2004) .
Death receptor stimulation alone often results only in a temporary tumour cell reduction. However, combined modality treatment of irradiation and TRAIL receptor stimulation enhances the rate of cell death when compared to either treatment alone (Chinnaiyan et al., 2000; Belka et al., 2001; Kim et al., 2001; Shankar et al., 2004a; Marini et al., 2005) . Initial results of phase 1 clinical studies for both antibodies show good compatibility and only mild non-specific toxicity in a wide array of haematopoietic and solid malignancies (de Bono et al., 2004; Hotte et al., 2004) . These encouraging results and results of prior preclinical studies have led us to study the combination of HGS-ETR1 and HGS-ETR2 with ionizing radiation in vitro in three colorectal tumour cell lines and in vivo in a colorectal xenograft mouse model. Here, we show for the first time that the combination of these novel monoclonal antibodies with ionising radiation significantly increases cell death in vitro and delays tumour growth in vivo.
The difference in the magnitude of induction of cell death between the two antibodies may be related to different levels of TRAIL-R1 and TRAIL-R2 cell surface expression. All three colorectal cell lines express TRAIL-R2, although at different levels. TRAIL-R1 expression is considerably lower in all lines compared to TRAIL-R2. This is consistent with data from Humphreys and coworkers, who found low expression of TRAIL-R1 in several solid tumour cell lines (Robin Humphreys, personal communication). This may explain why in all tested colorectal cell lines, HGS-ETR2 was more active compared to HGS-ETR1. However, there is evidence that TRAIL-R expression does not always correlate with sensitivity to TRAIL-R ligands Luciano et al., 2002) .
Independent of receptor surface expression, the Colo 205 cell line was most sensitive to any of the applied n.s. n.s. Figure 4 Comparison of the induction of apoptosis after simultaneous and sequential treatment. Apoptosis was determined by microscopic evaluation of Hoechst-stained cell nuclei 48 h after simultaneous (gray columns) and sequential (12 h before antibody application; black columns) treatment with HGS-ETR1 or HGS-ETR2 or both antibodies together (0.1 mg/ml) and 10 Gy for Colo 205 and HCT-15 cells. HCT 116 wild-type cells were treated with HGS-ETR1, HGS-ETR2 or both antibodies together (1.0 mg/ml) and 10 Gy. The columns depict the rate of apoptosis after combined treatment less the rate of irradiation alone. Data represent means of three independent experiments; bars7s.d. Combined therapy with agonistic TRAIL antibodies and radiotherapy P Marini et al treatments, whereas HCT-116 wt cells appear nearly radio-resistant. Nevertheless, in these cells, an increase in apoptosis induction could be measured after combined treatment with ionising radiation and either TRAIL receptor antibody. This suggests that radioresistance may be overcome by death receptor stimulation (Chinnaiyan et al., 2000; Marini et al., , 2005 Shankar et al., 2004b) . In how far the redox regulation of irradiated and TRAIL receptor-stimulated tumour cells is involved in the synergistic efficacy of a combined treatment has been studied by Hamasu et al. (2005) . The authors demonstrated an influence of the intracellular redox status on receptor upregulation. However, receptor upregulation seems to be only a part in the puzzle of sensitisation to the combined treatment (Marini et al., 2005) .
Another possible mechanism was proposed by Broaddus et al. (2005) . Their data suggest that the synergistic effect between TRAIL and other DNA-damaging agents depends on BH-3 only protein, Bid. Thus, the increase in the rate of apoptosis after combined treatment with agonistic TRAIL receptor antibodies and irradiation might be mediated by activation of Bid. However, we and other authors could demonstrate that the enhanced efficacy of a combined treatment with TRAIL receptor stimulation and ionising radiation is also dependent on the BH3-only protein Bax. Bak, a proapoptotic Bcl-2 homologue of Bax, cannot mediate this effect (von Haefen et al., 2004; Wendt et al., 2005) .
To ensure that efficacy of agonistic TRAIL receptor antibodies was not limited to the in vitro setting, we examined the effect of combination treatment in the Colo 205 mouse xenograft model as described in detail above. Similar to our results obtained in vitro, a dosedependent effect on tumour growth was observed with both antibodies. HGS-ETR2 led to the most prominent tumour growth delay. At the highest dose (10 mg/kg body weight), tumour regression was apparent after the first of three applications. Reduction in tumour size was so significant that additional growth delay when HGS-ETR2 was combined with radiation could not be demonstrated. Combined treatment with HGS-ETR1 and fractionated radiation led to a significant delay in tumour growth. The most prominent effect was seen at the highest antibody concentration applied.
Other authors have achieved similar results in a nude mouse model with breast cancer xenografts, but only for an anti-TRAIL-R2 antibody (Chuntharapai et al., 2001; Buchsbaum et al., 2003) . The treatment schedule we used in our study achieved for both anti-TRAIL receptor antibodies (anti-TRAIL-R1 and anti-TRAIL-R2) a Figure 6 Bax dependence of apoptosis induction after combined treatment. Apoptosis was determined in bax wild-type (hatched columns) and knockout (À/À; black columns) HCT 116 tumor cells by microscopic evaluation of Hoechst-stained cell nuclei 48 h after simultaneous treatment with HGS-ETR1, HGS-ETR2 (each 1.0 mg/ml) or both antibodies together with 10 Gy. Upper right panel: as control cell lines were examined by immunoblot analysis for Bax and Bak protein expression; b-Actin staining was used as loading control. The mapped blot represents one of three independently performed immunoblots. Combined therapy with agonistic TRAIL antibodies and radiotherapy P Marini et al more pronounced tumour growth delay. The advantage of the antibodies used in this study is that they are fully human, and thus our data should support application in multimodality settings in clinical trials. It is very difficult to compare our data with studies on TRAIL and irradiation given the lack of such experimental designs for colorectal tumours (Chinnaiyan et al., 2000; Shankar et al., 2004b) . However, a clinical phase I study with Apo2L/TRAIL in a single agent setting has been started in the fall of 2004 (A Ashkenazi, personal communication). Provided a hopefully positive outcome for this study, Apo2L/TRAIL could be another potential candidate for combination with DNA-damaging treatments (Rohn et al., 2001; Belka et al., 2003 Belka et al., , 2004 El-Zawahry et al., 2005) .
Combination of death receptor stimulation with other mitochondrial pathway-dependent substances might also disclose new options for therapy-resistant tumours such as glioblastoma or neuroblastoma. Combinations with TRAIL pathway agonists and the second mitochondrial activator of caspases or the intravenously applicable alkylphosphocholine derivate erucylphosphocholine represent promising trials to overcome resistance and restore sensitivity for receptor-and mitochondrialinduced apoptosis (Fulda et al., 2002; Jendrossek et al., 2003; Rubel et al., 2006) . Taken together, despite the critical dose relations for HGS-ETR2 in our xenograft experiments, we were able to show as a proof of principle that the novel TRAIL receptor antibodies HGS-ETR1 and HGS-ETR2 significantly enhance apoptotic cell kill and delay xenograft tumour growth, in particular when combined with ionizing radiation. We thus postulate that death receptor stimulation by agonistic antibodies in combination with radiation therapy or other mitochondrial pathway-dependent agents may prove a promising treatment option in colorectal and possibly other cancers.
Materials and methods

Chemicals
All biochemicals were obtained from Sigma-Aldrich chemicals (Deisenhofen, Germany) unless otherwise specified. Hoechst 33342 was purchased from Calbiochem (Darmstadt, Germany) and dissolved in distilled water as 1.5 mM stock solution.
Irradiation
Irradiation was performed with a linear accelerator (Elekta, Crawley, UK) with about 400 cGy/min dose rate and 6 MV photons. For in vitro experiments, tumour cells were irradiated directly in cell culture flasks or six-well plates at room temperature. [days]
[days]
[days] Combined therapy with agonistic TRAIL antibodies and radiotherapy P Marini et al Animals were treated in a special experimental device described earlier (Stu¨ben et al., 1994) . Shielding reduced the dose to the animal body to less than 3% of the prescribed dose. Ten mice were irradiated simultaneously on the right hind leg while under general anaesthesia with enflurane.
Cell culture
The tumour cell lines Colo 205 and HCT-15 cells were purchased from ATCC (Bethesda, MD, USA). HCT 116 Bax wt and knockout were kindly provided by Bert Vogelstein (Johns Hopkins University, MD, USA). All cells were grown in RPMI 1640 medium (Gibco Life Technologies, Eggenstein, Germany) with 10% fetal calf serum (FCS) and 1% penicillin/ streptomycin and maintained in a humidified incubator at 371C and 5% CO 2 .
TRAIL receptor stimulation
In vitro TRAIL receptor stimulation was performed with the agonistic TRAIL receptor antibodies HGS-ETR1 and HGS-ETR2 from Human Genome Sciences Inc. (Rockville, MD, USA) in concomitant or sequential application with irradiation.
For in vivo receptor stimulation, antibodies were applied intraperitoneally (i.p.) on days 1, 4 and 8 of the treatment directly after irradiation. The injected volume was 0.1 ml per 10 g body weight.
Receptor expression Cells (0.2 Â 10 6 ) were collected, washed twice with phosphatebuffered saline and incubated for 30 min with phycoerythrinlabelled anti-TRAIL-R1/DR4 or TRAIL-R2/DR5 antibody (R&D Systems, Wiesbaden-Nordenstadt, Germany) at a dilution of 1:400 in 0.5% FCS/PBS. Analyses of superficial receptor expression were performed by flow cytometry with fluorescene-activated cell sorter Calibur from Becton and Dickinson (Heidelberg, Germany).
Quantification of apoptosis induction
Apoptosis induction was quantified by counting of cells with characteristic apoptotic morphology after DNA staining with Hoechst 33342. Cells were stained by incubation with Hoechst 33342 at a final concentration of 1.5 mM for 15 min at 371C. Microscopy was performed using a Zeiss Axiovert 200 microscope (Carl Zeiss, Jena, Germany) with an excitation wavelength filter of 380 nm. All apoptotic levels were means of at least three independent experiments. The given error bars represent the standard error of the mean from independent measurements.
Western blot analysis Cells (1 Â 10 6 ) were lysed in a CST (3 Â ) lysis buffer from Cell Signaling (Frankfurt, Germany) containing 65 mM Tris-HCl, 2% sodium dodecyl sulphate (SDS), 10 glycerol, 50 mmol dithiothreitol (pH 6.8) and diluted 1:2 (v/v) in (1 Â ) PBS. After removing insoluble material by centrifugation for 10 min at 13 000 r.p.m., 10 ml of lysates was separated by SDS-polyacrylamide gel electrophoresis. Blotting was performed employing a tank blotting apparatus (Bio-Rad, Muenchen, Germany) onto Hybond C membranes (Amersham, Braunschweig, Germany). Blots were blocked in TBS buffer containing 5% non-fat dry milk in (1 Â ) TBS at room temperature for 15 min. Primary antibodies were detected after repeated washings with TBS/Tween 20 (0.1%) of the membrane, using a secondary antibody (anti-IgG-AP 1:10 000, Santa-CruzBiotech, Heidelberg, Germany) diluted in TBS/Tween and incubated for 3 h at room temperature and washed three times with TBS/Tween. Detection of antibody binding was performed employing enhanced chemoluminescence (CSPD s -Solution Tropix, Applied Biosystems, MA, USA). PARP cleavage was tested using polyclonal antibodies for cleaved and uncleaved PARP from Boehringer (Mannheim, Germany) in a 1:1000 dilution. Monoclonal antibodies for caspase-8 were a kind gift from Professor K Schulze-Osthoff, and were used in a 1:45 dilution. b-Actin (Santa Cruz, Heidelberg, Germany) antibody was used in a 1:5000 dilution.
Experimental animals
Immunodeficient NMRI (nu/nu) nude mice were bred in a specific pathogen-free animal colony at the University of Essen, Germany. At an age of 4-6 weeks, animals were brought to Tuebingen University and housed in an individually ventilated cage rack system (Techniplast, Italy). They were fed with sterile, high-calorie laboratory food (Sniff, Germany) and drinking water was supplemented by chlorotetracycline and potassium sorbate acidified to a pH of 3.0 with hydrochloric acid. All animal experiments were performed in accordance with the standard required by the German animal welfare regulations.
Transplantation and experimental design
For the experiments, a source tumour was excised and tumour chunks of about 2 mm diameter were implanted subcutaneously into the right hind limb of 6-to 10-week-old animals. Wound closure was not necessary. Approximately 2-3 weeks after transplantation, visible tumour growth occurred. According to results of previous experiments (data not published), a single dose of 3 Gy was chosen during fractionated radiotherapy.
Tumour size was measured with calipers in two perpendicular diameters. The tumour volume (V) was calculated as V ¼ (ab 2 )/2, where a and b are the long axis and the short axis, respectively. Scoring of tumour sizes took place three times per week before start of treatment. Body weight was recorded once a week.
When tumours reached a volume of 100-150 mm 3 , animals were randomly allocated to the following treatment arms: HGS-ETR1 at days 1, 4 and 8 with a dosage of (a) 0.1 mg/kg, (b) 1.0 mg/kg or (c) 10 mg/kg body weight i.p.; HGS-ETR2 at days 1, 4 and 8 with a dosage of (d) 0.1 mg/kg, (e) 1.0 mg/kg or (f) 10 mg/kg body weight i.p.; (g) fractioned radiotherapy (5 Â 3 Gy in 5 days). Combined treatment at days 1, 4 and 8 with HGS-ETR1 at a dosage of (h) 0.1 mg/kg, (i) 1.0 mg/kg or (j) 10 mg/kg or with HGS-ETR2 with (k) 0.1 mg/kg, (l) 1.0 mg/ kg or (m) 10 mg/kg body weight and fractioned radiotherapy (5 Â 3 Gy at days 1-5), (n) only medium without antibody and no radiotherapy (control animals).
Experiments were performed in one run with 115 animals. The median tumour volume at the start of experiments was 126 mm 3 . After starting treatment, tumour volume was scored twice per week. The investigators were not blinded as to the treatment that the animals had received, when they made their measurements. Follow-up was terminated at day 90 or if tumour volume had grown to eight times the initial tumour volume at the start of treatment. Tumour growth outlay was the endpoint of the study.
Statistical analysis
Analysis of tumour growth delay in xenograft experiments was based on the method of (Kaplan and Meier (1958) . Reaching the eightfold of the initial tumour volume was defined as the end point of the study. In case of an intercurrent death of single animals, median growth delay was corrected as described previously by Stuschke et al. (1990) . Statistical significance was ascertained with Graph Pad Prism s 3.0.
